1051 related articles for article (PubMed ID: 33711272)
21. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
22. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
24. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
25. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
26. Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus.
Colli LM; Jessop L; Myers TA; Camp SY; Machiela MJ; Choi J; Cunha R; Onabajo O; Mills GC; Schmid V; Brodie SA; Delattre O; Mole DR; Purdue MP; Yu K; Brown KM; Chanock SJ
Am J Hum Genet; 2021 Sep; 108(9):1590-1610. PubMed ID: 34390653
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
28. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
29. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
30. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
31. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
32. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.
Romo de Vivar Chavez A; de Vera ME; Liang X; Lotze MT
Med Oncol; 2009; 26 Suppl 1():3-12. PubMed ID: 19148593
[TBL] [Abstract][Full Text] [Related]
33. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.
Zhang Y; Narayanan SP; Mannan R; Raskind G; Wang X; Vats P; Su F; Hosseini N; Cao X; Kumar-Sinha C; Ellison SJ; Giordano TJ; Morgan TM; Pitchiaya S; Alva A; Mehra R; Cieslik M; Dhanasekaran SM; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099557
[TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
35. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma.
Nguyen HM; Oladejo M; Paulishak W; Wood LM
Cancer Immunol Immunother; 2023 Sep; 72(9):2889-2903. PubMed ID: 36562824
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
37. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
Norian LA; Kresowik TP; Rosevear HM; James BR; Rosean TR; Lightfoot AJ; Kucaba TA; Schwarz C; Weydert CJ; Henry MD; Griffith TS
PLoS One; 2012; 7(2):e31085. PubMed ID: 22312440
[TBL] [Abstract][Full Text] [Related]
38. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
39. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
[TBL] [Abstract][Full Text] [Related]
40. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
